HTB | HIV i-Base

CROI 2023: frist reports...

Featured HTB March 2023 (10 March 2023) 10 March 2023. Related: Editorial.
Featured HTB January/February 2023 (1 February 2023) 1 February 2023. Related: Editorial.
Featured HTB November/December 2022 (16 December 2022) 16 December 2022. Related: Editorial.
Featured In memory: Timothy Ray Brown – the Berlin patient, the first person to be cured of HIV 14 October 2020. Related: In memory.
Cases of mpox reinfection in HIV negative men on PrEP: atovaquone, mefloquine and molnupiravir as potential treatments 15 March 2023. Related: Early access, mpox (monkeypox).
30th Conference on Retroviruses and OIs (CROI 2023): first reports 10 March 2023. Related: Conference reports, Conference index, CROI 30 (Retrovirus) 2023.
CROI 2023: Pipeline HIV drugs and formulations for treatment and PrEP 10 March 2023. Related: Conference reports, Antiretrovirals, CROI 30 (Retrovirus) 2023.
CROI 2023: Six-monthly ART – lenacapavir + dual bNAbs maintains undetectable viral load for 26 weeks after single doses 10 March 2023. Related: Conference reports, Antiretrovirals, CROI 30 (Retrovirus) 2023.
CROI 2023: Other lenacapavir studies – experienced and naive updates, the dosing window, HIV-2 and PrEP 10 March 2023. Related: Conference reports, Antiretrovirals, CROI 30 (Retrovirus) 2023.
CROI 2023: Similar PK profile for thigh vs gluteal CAB/RPV-LA injections: accidental intravenous injection 10 March 2023. Related: Conference reports, Antiretrovirals, CROI 30 (Retrovirus) 2023.
CROI 2023: Efficacy of N6LS monotherapy correlated with baseline factors 10 March 2023. Related: Conference reports, Antiretrovirals, CROI 30 (Retrovirus) 2023.
CROI 2023: CAB/RPV-LA levels are not reduced after switching from efavirenz 10 March 2023. Related: Conference reports, PK and drug interactions, CROI 30 (Retrovirus) 2023.
CROI 2023: Yet more evidence for recycled tenofovir and 3TC or FTC with dolutegravir in second-line: 48 week results from the D2EFT study 10 March 2023. Related: Conference reports, Treatment strategies, Resistance, CROI 30 (Retrovirus) 2023.
CROI 2023: Point-of-care testing for mothers and infants: results from the LIFE study 10 March 2023. Related: Conference reports, Pregnancy, Paediatric care, CROI 30 (Retrovirus) 2023.
CROI 2023: Bone density profiles for CAB-LA vs TDF/FTC oral PrEP in young people 10 March 2023. Related: Conference reports, Side effects, HIV prevention and transmission.
CROI 2023: Single dose doxycycline as PEP for STIs (DoxyPEP): five studies 10 March 2023. Related: Conference reports, Coinfections and complications, CROI 30 (Retrovirus) 2023.
CROI 2023: Severe mpox outcomes with a low CD4 count and detectable viral load: a new AIDS-defining condition? 10 March 2023. Related: Conference reports, mpox (monkeypox), CROI 30 (Retrovirus) 2023.
The Düsseldorf patient HIV cure case published in Nature Medicine 10 March 2023. Related: Cure research.
UK-CAB online training: webinar programme every two weeks 10 March 2023. Related: Treatment advocacy, On the web.
New community platform on HIV and mental health: in 10 EU languages 1 March 2023. Related: Treatment advocacy, Other news.
Supporting Ukraine 1 March 2023. Related: Editorial.
Training webinar: 2nd HIV from A to Z 1 March 2023. Related: On the web, Future meetings.
Future meetings and webinars 2023/24 1 March 2023. Related: Future meetings.
HTB: no. 1/2 (January/February 2023) PDF download 1 February 2023. Related: PDFs.
24th International Workshop on Long-term Complication of HIV and SARS-CoV-2 1 February 2023. Related: On the web.
30th Conference on Retroviruses and Opportunistic Infection (CROI 2023) 1 February 2023. Related: Conference reports, Conference index.
Glasgow HIV Congress (2022) 1 February 2023. Related: Conference reports, Conference index, HIV 16 Glasgow 2022.
Glasgow 2022: pipeline studies with bNAbs N6LS and maturation inhibitor GSK254 1 February 2023. Related: Conference reports, Antiretrovirals, HIV 16 Glasgow 2022.
Glasgow 2022: doravirine updates 1 February 2023. Related: Conference reports, Antiretrovirals, HIV 16 Glasgow 2022.
Glasgow 2022: long-acting cabotegravir/rilpivirine: adverse events, implementation and PROMs 1 February 2023. Related: Conference reports, Antiretrovirals, HIV 16 Glasgow 2022.
Glasgow 2022: community statement on HIV and ageing 1 February 2023. Related: Conference reports, Ageing and life expectancy, Treatment advocacy.
Lenacapavir approved in the US for multidrug resistant HIV 1 February 2023. Related: Antiretrovirals.
More evidence for recycling tenofovir in second-line ART with dolutegravir: 72-week results from ARTIST study 1 February 2023. Related: Antiretrovirals, Treatment strategies.
Low level viral load on effective ART is linked to clonal expansion of reservoir: not affected by modifying ART 1 February 2023. Related: Antiretrovirals, Treatment strategies, Guidelines, Resistance.
Integrase inhibitors associated with higher increases in CD4:CD8 ratio than PI- or NNRTI-based ART 1 February 2023. Related: Antiretrovirals, Treatment strategies.
Superinfection detected in up to 7% of people in Swiss HIV Cohort Study 1 February 2023. Related: Coinfections and complications, Resistance.
Zero transmission in France for mothers on ART from conception with undetectable viral load at delivery 1 February 2023. Related: Pregnancy.
Phase 3 Mosaico HIV vaccine efficacy trial stopped early due to lack of benefit 1 February 2023. Related: Vaccines and microbicides.
Update on mpox: sleeping or hiding? 1 February 2023. Related: mpox (monkeypox).
56 Dean Street as a nurse-led PrEP clinic: >20,000 clients in 2021 1 February 2023. Related: HIV prevention and transmission.
Potential to use BOTOX for erectile dysfunction 1 February 2023. Related: Coinfections and complications.
Cases of Kaposi’s Sarcoma (KS) in people on effective ART 1 February 2023. Related: Coinfections and complications.
Shorter course of less-intensive treatment for visceral leishmaniasis 1 February 2023. Related: Coinfections and complications.
In memory: Giulio Maria CorbellI and Chris Sandford 1 December 2022. Related: In memory.
Latest statistics on HIV in the UK: data for 2021 1 December 2022. Related: Special reports, HIV prevention and transmission.
Glasgow HIV Congress 2022 1 December 2022. Related: Conference reports, HIV 16 Glasgow 2022.
Glasgow 2022: Better re-suppression after viral rebound with DTG-based ART compared to EFV- or PI-based regimens 1 December 2022. Related: Conference reports, Treatment strategies, HIV 16 Glasgow 2022.
Glasgow 2022: Vertical transmission rate below 0.3% among women living with HIV in the UK 1 December 2022. Related: Conference reports, Pregnancy, HIV 16 Glasgow 2022.
Glasgow 2022: Impact of islatravir on lymphocyte counts in a dose-ranging study: a post-hoc analysis 1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Islatravir studies to use 0.25 mg daily dose to overcome risk of reducing CD4 and total lymphocytes 1 December 2022. Related: Conference reports, Antiretrovirals.
Glasgow 2022: Fostemsavir 240 week results from BRIGHTE study 1 December 2022. Related: Conference reports, Antiretrovirals.